Trials / Completed
CompletedNCT01903122
Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Roxane Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fasted conditions
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cevimeline |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2013-07-19
- Last updated
- 2018-01-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01903122. Inclusion in this directory is not an endorsement.